Alnyalm, Vir partner on RNAi-based hep B treatment

(Reuters) - Drug developer Alnylam Pharmaceuticals Inc said on Wednesday it would scrap its hepatitis B (HBV) drug development and instead work with Vir Biotechnology on a new treatment for the disease.